Table 1 Patient characteristics and CEC detection
Mean CEC level 166 cells/4 mL | Range (2–1195 cells/4 mL) | Total | P a | ||
|---|---|---|---|---|---|
≥ 166 cells/4 mL | <166 cells/4 mL | ||||
CEChigh | CEClow | ||||
12 | 25 | 37 | |||
Age | Over 70 | 8 | 10 | 18 (49%) | 0.17 |
Below 70 | 4 | 15 | 19 (51%) | ||
Sex | Male | 7 | 17 | 24 (65%) | 0.72 |
Female | 5 | 8 | 13 (35%) | ||
Stage | III | 3 | 11 | 14 (38%) | 0.59 |
IV | 8 | 12 | 20 (54%) | ||
Recurrence | 1 | 2 | 3 (8%) | ||
ECOG PS | 0 | 5 | 18 | 23 (62%) | 0.09 |
1 | 6 | 4 | 10 (27%) | ||
2 | 1 | 3 | 4 (11%) | ||
Pancreatic tumor location | Head | 5 | 12 | 17 (46%) | >0.9 |
Body | 5 | 9 | 14 (38%) | ||
Tail | 2 | 4 | 6 (16%) | ||
CA19-9 (U/mL) | ≥10,000 | 3 | 5 | 8 (22%) | >0.9 |
< 10,000 | 9 | 20 | 29 (78%) | ||
CRP (mg/dL) | ≥1.0 | 7 | 3 | 10 (27%) | <0.01 |
<1.0 | 5 | 22 | 27 (73%) | ||
Histology | Poorly differentiated | 5 | 9 | 14 (38%) | 0.62 |
Moderately differentiated | 4 | 10 | 14 (38%) | ||
Adenosquamous | 1 | 0 | 1 (2%) | ||
N.E (cytology only) | 2 | 6 | 8 (22%) | ||
Tumor response | Partial response | 2 | 2 | 4 (11%) | <0.05 |
Stable disease | 4 | 18 | 22 (59%) | ||
Progressive disease | 6 | 5 | 11 (30%) | ||
Second line therapy | S-1 | 6 | 12 | 18 (49%) | 1 |
Oxaliplatin + S-1 | 0 | 2 | 2 (5%) | ||
No | 6 | 11 | 17 (46%) |